Unknown

Dataset Information

0

Neutralizing antibodies for HIV-1 prevention.


ABSTRACT: PURPOSE OF REVIEW:In the absence of a protective vaccine against HIV-1, passive immunization using novel broadly neutralizing antibodies (bNAbs) is an attractive concept for HIV-1 prevention. Here, we summarize the results of preclinical and clinical studies of bNAbs, discuss strategies for optimizing bNAb efficacy and lay out current pathways for the development of bNAbs as prophylaxis. RECENT FINDINGS:Passive transfer of second-generation bNAbs results inpotent protection against infection in preclinical animal models. Furthermore, multiple bNAbs targeting different epitopes on the HIV-1 envelope trimer are in clinical evaluation and have demonstrated favorable safety profiles and robust antiviral activity in chronically infected individuals. The confirmation that passive immunization with bNAb(s) will prevent HIV-1 acquisition in humans is pending and the focus of ongoing investigations. Given the global diversity of HIV-1, bNAb combinations or multispecific antibodies will most likely be required to produce the necessary breadth for effective protection. SUMMARY:Encouraging results from preclinical and clinical studies support the development of bNAbs for prevention and a number of antibodies with exceptional breadth and potency are available for clinical evaluation. Further optimization of viral coverage and antibody half-life will accelerate the clinical implementation of bNAbs as a critical tool for HIV-1 prevention strategies.

SUBMITTER: Julg B 

PROVIDER: S-EPMC7341949 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Neutralizing antibodies for HIV-1 prevention.

Julg Boris B   Barouch Dan H DH  

Current opinion in HIV and AIDS 20190701 4


<h4>Purpose of review</h4>In the absence of a protective vaccine against HIV-1, passive immunization using novel broadly neutralizing antibodies (bNAbs) is an attractive concept for HIV-1 prevention. Here, we summarize the results of preclinical and clinical studies of bNAbs, discuss strategies for optimizing bNAb efficacy and lay out current pathways for the development of bNAbs as prophylaxis.<h4>Recent findings</h4>Passive transfer of second-generation bNAbs results inpotent protection agains  ...[more]

Similar Datasets

| S-EPMC8329589 | biostudies-literature
| S-EPMC8606861 | biostudies-literature
| S-EPMC5314445 | biostudies-literature
| S-EPMC4935580 | biostudies-literature
| S-EPMC7375352 | biostudies-literature
| S-EPMC7340121 | biostudies-literature
2020-01-28 | GSE141498 | GEO
| S-EPMC4779134 | biostudies-literature
| S-EPMC7690876 | biostudies-literature
| S-EPMC5165208 | biostudies-literature